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Summary 
The Consolidated Standards Of Reporting Trials (CONSORT) extension for the stepped-wedge cluster randomised 
trial (SW-CRT) is a recently published reporting guideline for SW-CRTs. We assess the quality of reporting of a recent 
sample of SW-CRTs according to the 26 items in the new guideline using a novel crowd sourcing methodology 
conducted independently and in duplicate, with random assignment, by 50 reviewers. We assessed reliability of the 
quality assessments, proposing this as a novel way to assess robustness of items in reporting guidelines.  
Several items were well reported. Some items were very poorly reported, including several items that have unique 
requirements for the SW-CRT, such as the rationale for use of the design, description of the design, identification 
and recruitment of participants within clusters, and concealment of cluster allocation (not reported in more than 
50% of the reports). Agreement across items was moderate (median percentage agreement was 76% [IQR 64 to 86]). 
Agreement was low for several items including the description of the trial design and why trial ended or stopped for 
example.  
When reporting SW-CRTs authors should pay particular attention to ensure clear reporting on the exact format of 
the design with justification, as well as how clusters and individuals were identified for inclusion in the study, and 
whether this was done before or after randomisation of the clusters, which are crucial for risk of bias assessments. 
Some items, including why the trial ended might either not be relevant to SW-CRTs, or might be unclearly described 
in the statement.  
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Introduction 
The stepped-wedge cluster randomised trial (SW-CRT) is a novel cluster randomised trial design that is particularly 
valuable in implementation research and becoming more commonly used [Brown 2006; Mdege 2011, Martin 2016]. 
It is particularly relevant for evaluating service innovations in learning healthcare organisations [Hemming 2015]. The 
SW-CRT involves randomisation of clusters (e.g. primary care units, wards, hospitals) to different sequences that 
dictate the order in which each cluster will switch to the intervention condition [Hussey and Hughes 2007]. The 
CONSORT (Consolidated Standards Of Reporting Trials) statement, which outlines key characteristics to be reported 
in a parallel arm individually randomised trial [Schulz 2010], has recently been extended to provide a reporting 
guideline specific to SW-CRTs (referred to as the CONSORT extension for the SW-CRT) [Hemming 2018]. Whilst the 
earlier CONSORT extension for cluster randomised trials provides reporting guidance for trials in which groups of 
individuals (clusters) are randomised [Campbell 2012], there are many differences between the SW-CRT and the 
parallel cluster trial.  
Key design characteristic of the SW-CRT (which do not typically feature in a parallel CRT conducted at a single cross 
section) include whether the design repeatedly measures the same individuals [Copas 2015]; whether the study is 
designed with an equal number of clusters allocated to each sequence; whether the study incorporates a transition 
period (a time period in which the intervention is embedded into practice) [Hemming 2015]; whether participants 
are recruited into the study before randomisation; whether cross-sectional samples are selected for outcome 
assessment; and whether outcomes are ascertained for a complete enumeration of the cluster members using 
routinely collected data. Furthermore, the design is also susceptible to several risks of biases particular to the SW-
CRT: including confounding with time [Hemming 2017]; complex within-cluster correlation patterns [Girling 2016; 
Hooper 2016; Kasza 2017; Thompson 2018]; the risk of within-cluster contamination [Copas 2015; Hemming 2018]; 
the possibility of time varying treatment effects [Davey 2015, Hemming 2017]; and risks of recruitment or selection 
biases [Higgins 2016; Caille 2016].  
Several systematic reviews have examined the quality of reporting of SW-CRTs. These have reported lack of clarity of 
the design, reporting of time adjustments, and key ethical aspects such as consent and ethical oversight [Brown 
2006; Mdege 2011; Martin 2016; Grayling 2017; Taljaard 2017]. Whilst only about 40 completed SW-CRTs have  been 
identified by these reviews, there has been an exponential increase in the use of this design over the past few years 
with an expected further increase in the near future.  
Here we report the results of a systematic review of an assessment of the quality of reporting of a recent sample of 
SW-CRTs according to the newly developed reporting guideline. The aims of this review were to determine the 
quality of reporting of a recent set of SW-CRTs according to this newly developed guideline, to flag areas that are 
particularly poorly reported (to encourage immediate improved reporting), and to provide a baseline assessment for 
future studies examining any changes over time. This assessment of quality of reporting was conducted by 50 
reviewers, with random assignment, so that each assessment of quality of reporting was performed independently 
by two reviewers. This was followed by a discussion to resolve differences, leading to a joint assessment. Whilst not 
a primary aim, we also assessed the reliability of the independent assessments. Measures of reliability of the 
independent assessments was used to suggest potential items in the statement where the wording might be 
unclear.  
Methods 
We identified a sample of recently published SW-CRT trials, which were then randomly allocated to 50 reviewers for 
quality assessment. We capitalised on the willingness, interest and skill set of participants (the reviewers) attending 
a workshop on the reporting of SW-CRTs in London, UK during November 2017. To allow for independent extraction 
by two reviewers per trial report, and to allow for the possibility of more participants than expected attending the 
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workshop we sought to identify approximately 30 SW-CRT trial reports. Specific objectives were to assess agreement 
between reviewers and to provide a joint assessment of the quality of reporting according to the new CONSORT 
extension for this trial design. 
 
Scope of this review 
We included SW-CRTs with a minimum of three sequences (where a sequence is defined as a unique allocation of 
periods spent in the control condition followed by periods in the intervention condition). One exception was made 
to this criteria to include trials with two sequences and three periods, which are also considered SW-CRTs by the 
new reporting guideline. We included only studies comparing two treatment conditions. We did not restrict inclusion 
to those designs with all clusters initiating in the control condition and ending up in the intervention condition. Only 
studies using the cluster as the unit of randomisation were included. We included only primary reports of SW-CRTs; 
protocols and reports of secondary analyses of a previously reported trial were excluded. Reports had to be open 
access or viewable from either the University of Birmingham or University of Ottawa libraries, and published in 
English. Focusing on the most recently published trials helped ensure our assessment of reporting quality was 
current and avoided any overlap with earlier systematic reviews of SW-CRTs. A protocol for the review was not 
registered with PROSPERO as it was out of remit.  
 
Search strategy 
We identified eligible studies in MEDLINE (accessed using PubMed) using a previously published electronic search 
strategy [Martin 2016, Table S1] run on the 21st November 2017 (including variations of the search terms “stepped 
wedge”, “experimentally stated introduction”, “delayed intervention”). We identified and ordered studies in 
descending order by date listed in Medline. To allow for exclusion of ineligible studies, titles and abstracts of the first 
50 studies were identified. The title and abstracts of these 50 studies were screened independently by two authors 
(KH and MT). Those found not to meet the eligibility criteria were excluded. Any differences were resolved by 
discussion. Those studies not meeting the eligibility criteria were excluded. For the remaining studies, full copies of 
the trial reports were then obtained and assessed against the inclusion criteria.   
 
Data abstraction process 
Data abstraction was undertaken by delegates attending a workshop in London on the reporting of SW-CRTs on 30 
November 2017. The workshop was run as part of an annual methodological meeting (including workshops and 
short invited and contributed talks) on current developments in cluster randomised and stepped-wedge trials. The 
workshop was a low cost (£50) event with open attendance, but for which pre-registration was necessary. 
 
In preparation for the event we invited all registered delegates to participate in the review. Participants were 
informed that attending the workshop would require undertaking a small amount of work in advance and during the 
event, with an invitation to contribute to the resulting manuscript as a group author. Anyone not wishing to 
participate in the development of the paper was invited to opt out (by 24 November), and any collected data would 
be excluded should the participant so wish. Participants were also informed that data on inter-rater reliability as well 
as the quality of reporting would be anonymously evaluated. Participants were free to not participate in this activity 
whilst still attending the meeting.  
Participants not opting out were randomly allocated to one of the trial reports using computer-generated numbers, 
so that two participants were allocated to each study. One week in advance of the meeting, a full PDF copy of their 
allocated study was e-mailed to each participant. Participants were asked to independently assess the quality of 
reporting according to the 26 items in the newly proposed CONSORT extension for SW-CRTs (using a simple tool 
provided Appendix 1). Participants were kept blind to the other allocated assessor of the same report until the 
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morning of the workshop. Participants were requested to bring a hard copy of the completed quality of reporting 
assessment tool with them to the workshop.  
At the beginning of the workshop participants listened to a 30-minute presentation (by KH and MT) summarising the 
most salient points of the new reporting guideline. After this, the two participants assigned to each trial report met 
for a 30 minute period, discussed any discrepancies and reached a consensus for each of the 26 quality assessment 
items (hereafter called the joint assessment). Two facilitators (KH and MT) provided advice on any issues of clarity. 
At the end of the workshop, participants submitted their completed independent assessments (which they were 
asked not to change during the joint assessment process) and joint assessments. Data were therefore abstracted 
independently and in duplicate for each trial report.  
Data abstracted 
For each item, participant reviewers were provided with the wording of the checklist item and asked to assess 
whether the item was reported in their assigned study (Appendix 1). Reviewers were asked to assess the quality of 
reporting for each of the 26 items according to a four-point scale (clearly reported in full / clearly but partially 
reported / unclearly reported / not reported). However, feedback from reviewers following the independent 
assessment indicated the need for a “not applicable” response in the scale. As a consequence, the response scale 
was changed to a five-point scale with the addition of “not applicable” for the joint assessment. All reviewers 
completing the joint assessment were made aware of this change of scale. Some independent assessments also 
independently decided to add a “not applicable” option; whereas others did not. Several of the 26 items have two or 
three sub-items, leading to a total of 40 items undergoing assessment. The data were abstracted and entered into an 
Excel database by one person (KH).  
 
Statistical analysis 
First, we described for each item, the reliability of the quality assessment using percentage agreement (within item 
across pairs) and the Gwet A1 statistic [Gwet 2013] using the kappaetc  command in Stata 14, chosen because the 
study design was of reviewers nested within articles. Percentage agreements were compared using the four-point 
scale, and by dichotomising the four-point scale into a two-point scale (clearly reported including clearly reported in 
full or clearly but partially reported versus not clearly reported which includes unclearly reported or not reported). 
Independent reviews were excluded from the assessments of reliability if only one of the pair submitted their 
independent assessments (n=3). Any individual level items which were missing in either one or both independent 
assessments were also excluded (numbers included provided in tables), as were any assessments of not applicable 
because this was not included in the independent assessment tool. Items with low agreement might be considered 
to be items that are less clearly described in the statement than those with higher agreement.  
 
We then described the joint assessment based on the consensus achieved between the reviewer pairs of reporting 
quality for all 26 items, along with the average number of items clearly reported for each report (or assessed as not 
applicable). Here, items assessed as not applicable were counted as clearly  reported as all reviewers were aware of 
the inclusion of the category not applicable at the joint assessment stage and because this was deemed the best way 
not to penalise the assessment of quality of reporting when items were deemed not applicable. Any item 
assessments missing from the joint assessments were excluded (10 out of a total of 1000 possible assessments).  
 
Finally, for completeness we describe for paper and each pair of reviewers the percentage agreement across items 
(within pair across items) and the corresponding  measure of reliability (again excluding any assessments of not 
applicable, missing independent assessments and missing individual item assessments). Reviewer pairs with very low 
(or very high) agreement might indicate reviewers with low (or high) expertise or papers that are clearly (or 
unclearly) reported. Alongside this, we report the joint assessment of quality of reporting for each study.  
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Results 
Identified studies 
The initial search identified 437 potential articles for inclusion (Figure 1). The most recently published 50 of these 
were screened in duplicate. Of these 50 studies, 7 were excluded because they were not randomised; 7 because 
they were protocols and not full reports; 4 because they were individually randomised; 3 because they reported a 
secondary analysis; 1 because it was a methods paper; and an additional two because they were not accessible. Of 
these exclusions, two were excluded in the full paper screen (one secondary analysis; and one because it did not 
clearly randomise clusters); and the others were excluded on the abstract screen. This therefore meant a total of 24 
studies were excluded; leaving 26 for inclusion. One study was later identified as not meeting the inclusion criteria 
by a reviewer and so was also excluded (individually randomised); leaving 25 trial reports for inclusion in the 
analysis. A description of the 25 studies is provided in Table 1. 
 
Participant reviewers 
A total of 53 participants registered for the workshop. Of these, three participants (AF, JT and group author JM who 
were all participants of the Delphi group in the development of the extension statement) were asked to be reserve 
reviewers. Of the remaining 50 participants four dropped out (one dropped out before the day, one was a duplicate 
registration and two did not attend on the day). One participant on the waiting list to attend the workshop was 
invited to attend to replace the participant who dropped-out before the event.  
The three participants invited to act as reserves all attended the event and each acted as a replacement for the three 
participants who did not attend the workshop (two of these provided an independent assessment for their 
subsequently allocated paper, one of which was done un-blinded to the other reviewers assessment). At the end of 
the event, 47 independent assessments were provided some of which included missing items (two of the invited 
participants did not return their independent assessment at the end of the workshop) and we received 25 
completed joint assessments on 25 trials. 
The participants were mainly from the UK (84%); the majority worked in University settings (72%); and most were 
statisticians although a number were clinicians (18%) spanning a range of career levels; with most having being 
involved some way in a stepped-wedge trial and a small number having participated in development of CONSORT 
statements (Supplementary Table S1).  
Reliability of quality assessments 
Some items showed very high agreement (observer percentage agreement) across the independent assessments, 
within items and across reviewer pairs (Table 2; Supplementary Figure S1). For example, reviewers were in 
agreement 100% of the time as to whether the title was clearly reported (Item 1a). Reviewers were also very often in 
agreement for the reporting of Item 5 (Interventions); Item 10c (Consent); Item 23 (Trial registration); Item 24 
(Protocol) and item 26 (Funding). Some items showed particularly poor agreement across independent assessments. 
These included Item 3a (trial design); item 8b (Type of randomisation); Item 11b (If relevant, description of the 
similarity of the treatments); item 13a (Flow diagram); Item 14b (Why the trial ended) and Item 22 (Interpretation) 
all in agreement less than 60% of the time. Over all 26 items the median percentage agreement was 53% ([IQR: 43-
64]) and the median Gwet’s A1 statistic was 0.41 (IQR 0.29-0.55) when comparing agreement across the four 
possible assessment categories. Median agreement increased to 76% [IQR: 67-86] when the comparison was made 
across a two point scale. The median Gwet’s A1 statistic across all items on the two point score was 0.72 [IQR: 0.59 
to 0.90]. As expected, reliability was higher on the two point scale compared to the four point scale.  
  
Quality of reporting of SW CONSORT items in the 25 trial reports based on the joint assessment of reviewers 
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There was variability among trial reports in the quality of reporting (Table 3; Supplementary Figure S2), with the 
median number of items reported (clearly or partially) was 28 [IQR: 23 to 30] of a total of 40 separate items. Several 
items were assessed as being well reported in the joint assessment. These included Item 1b (structured summary); 
Item 4a (eligibility criteria) and Item 4b (setting and locations where data were collected); Item 5 (description of 
intervention and control conditions); Item 6a (outcomes); Item 15 (baseline table); Item 17a (results); Item 25 
(sources of funding and other support, role of funder); and Item 26 (whether the study was approved by a research 
ethics committee); all clearly reported more than 80% of the time.  
 
Other items were poorly reported. In particular, the following items were clearly reported less than 50% of the time 
(in order of appearance in the statement): Item 2a (rationale and justification for the trial design); Item 3a 
(description of trial design); Item 3b (important changes to methods after trial commencement); Item 6b (any 
changes to trial outcomes after the trial commenced); Item 11a (blinding); Item 19 (Important harms); Item 21 
(generalisability); and Item 24 (where the full trial protocol can be accessed, if available). All items involving 
randomisation were also poorly reported. This included Item 8a (methods used to generate the random allocation); 
Item 8b (type of randomisation); Item 9 (specification that allocation was based on the clusters; description of any 
methods used to conceal the allocation from the clusters until after recruitment); Item 10a (who generated the 
randomisation); and Item 10b (mechanism by which individual participants were included in the trial (such as 
complete enumeration, random sampling)).  
Quality of reporting for each paper and reliability within pairs of reviewers 
Making comparisons within reviewer pairs and across items, the percentage agreement (on a two-point scale) across 
all items ranged between 38% (reviewer pair 9) and 83% (reviewer pair 22). The median Gwet’s A1 statistic across all 
pairs was 0.42 [IQR: 0.36 to 0.51]. (Supplementary Table S2) The median number of items (out of the total of 40 sub-
items) assessed as being clearly reported was similar between the independent assessments (median [IQR] are 26 
[IQR 21 to 29] not shown in tables) and 28 [IQR 23 to 30] for the joint assessments - see above. 
Discussion  
Principal findings 
We have reported, using an innovative review approach capitalising on the interests and expertise of delegates at a 
workshop, an assessment of quality of reporting of SW-CRTs according to the new extension of the CONSORT 
statement for this trial design. Perhaps unsurprisingly we have identified sub-optimal reporting. Items particularly 
poorly reported were those items detailing the justification and design of the study and information on the method 
of randomisation, including the method of recruitment and allocation of clusters and participants. Some items with 
low reporting are specific to the SW-CRT (such as justification of the design); others are not specific and include such 
things as identification of the trial protocol. Two items, Item 11b (description of the similarity of the treatments) and 
Item 14b (why the trial ended or stopped) might not be relevant to many SW-CRTs despite their inclusion in the 
updated statement.  
 
Implications 
Clear reporting of who recruited or identified participants and whether or not such individuals were blind to 
allocation is important so readers can determine the risks for recruitment and selection biases [Higgins 2016; Caille 
2016]. We identified that a description of any methods used to conceal the allocation from the clusters until after 
recruitment was poorly reported, as was the mechanism by which individual participants were included in clusters 
for the purposes of the trial (such as complete enumeration or random sampling; continuous recruitment or 
ascertainment, or recruitment at a fixed point in time), including who recruited or identified participants [Copas 
2015; Hemming 2018]. In parallel cluster trials, it has recently been proposed that trials should report a timeline 
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diagram to allow clear identification of the timing of randomisation with respect to recruitment of clusters and 
participants [Caille 2016]. Whether such a diagram could be modified for the SW-CRT remains to be investigated.  
 
We also identified suboptimal reporting of the format of the design and justification for use of the SW-CRT. Clear 
reporting of the exact form of the design is necessary to determine whether the appropriate sample size and analysis 
methods have been used [Hooper 2016]. Clear reporting of the justification for use of the design is important to 
determine if the study is ethically appropriate [Hemming 2017b].  
 
Whilst some basic items were well reported, such as the title, sources of funding, and ethics review, a substantial 
minority of reports failed to report these essential details and many failed to report where the full trial protocol can 
be assessed. We identified that 32% of this very recent sample of SW-CRTs did not report trial registration clearly. 
Trial registration is known to increase transparency of reporting of primary outcomes and will deter against selective 
reporting [Mathieu 2009; Killeen 2014; Azar 2015]. Related to this, an earlier in-depth review of the quality of 
reporting of the ethical conduct and reporting of SW-CRTs identified poor reporting and identification of the 
research participant, informed consent and ethical review [Taljaard 2017]. In light of this, when the CONSORT 
extension for the SW-CRT was developed it introduced an extra item to encourage transparent reporting of ethical 
review. This review echoes previous findings and highlights how a significant minority of SW-CRTs fail to report any 
ethical review processes or provide details of the trial protocol; despite these being endorsed by the International 
Committee of Medical Journal Editors. These findings might indicate a misconception that SW-CRTs are different to 
conventional trials and do not need to be reported conducted with similar standards.  
 
What is already known 
The CONSORT statement describes a minimum set of items that should be reported in any clinical trial to ensure 
transparent reporting. Without transparent reporting the validity of the methods and the results cannot be assessed 
and this can have wide ranging medical implications [Rennie 2001]. Studies published in endorsing journals are more 
likely to report this minimum set of items than those that do not [Turner 2012]; and reviews have suggested an 
increase in quality of reporting post publication of reporting guidelines [Ivers 2011; Chan 2017].  
 
There have been several reviews of the quality of reporting of SW-CRTs. Early reviews however did not assess quality 
of reporting against the CONSORT items [Beard 2015]; other reviews, whilst assessing reporting against the 
CONSORT extension for cluster randomised trials, gave in-depth reviews, for example assessing quality of reporting 
of sample size [Martin 2016] or analysis items only [Davey 2015]. Reviews assessing quality of reporting against all of 
the items in the CONSORT extension for cluster trials have demonstrated, not surprisingly, sub-optimal reporting 
[Grayling 2017]. This sub-optimality might be explained partly by the necessary inclusion of older trials (to avoid an 
overly small sample size) and the lack of relevance or coherence of items written with an individually randomised or 
parallel cluster trial in mind.   
Strengths and limitations  
This methodological review used a novel approach to data abstraction, capitalising on the interest and willingness of 
a group of methodologists attending a small conference to undertake quality assessments.  The number of articles 
reviewed was small (25) but represents a substantial proportion of the total number of stepped-wedge trials 
undertaken to date (40 completed trial reports up to February 2015) [Grayling 2017]. Furthermore, the date range 
was selected to be mutually exclusive with other recent methodological reviews [Martin 2016; Grayling 2017]. Being 
the most recent year at the time of the review, our results reflect current reporting practices. There was some 
variation across reviewers in degrees of expertise and knowledge of the design, but all participants were given a 
short briefing via the introductory presentation. Reports were randomly allocated to the reviewers and data were 
abstracted independently to the other reviewers and then in duplicate. One important limitation is that participants 
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were asked to assess quality of reporting on a four-point scale for their independent assessment; this was changed 
to a five-point scale by adding the category “not applicable” for the joint assessment. On the four-point scale 
agreement was low; when agreement was considered on a two-point scale (i.e. reported partially or fully vs. not 
reported or unclearly reported) agreement improved. However, even on this two-point scale agreement was poor 
for some items. Items with low agreement might be less clearly worded in the trial reports than items with higher 
agreement.  
 
Whilst this review did not set out to explicitly identify items with unclear wording, some of our results might be 
suggestive of items with insufficient wording clarity. Any future revisions of the CONSORT statement for SW-CRTs 
might pay particular attention therefore to the wording and relevance of Items 11b (If relevant, description of the 
similarity of treatments) and 14b (Why the trial ended or was stopped).  Any robust attempt to study the clarity of 
the wording of CONSORT items would ideally be pre-planned, and include a range of diverse stakeholders (trialists, 
principal investigators, clinicians etc.) and likely include a qualitative assessment as well as a quantitative assessment 
of agreement.  
 
We also observed variability in agreements within pairs, with some pairs of reviewers consistently agreeing across 
items and other pairs of reviewers mostly disagreeing across items. Agreement may have been improved with 
additional training of assessors (there was no association between quality of the study report as assessed by the 
joint assessment and level of agreement of independent assessments – Table S2). 
 
Conclusions  
The CONSORT extension for SW-CRTs provides specific and tailored guidance for the reporting of SW-CRTs. Clear 
reporting is crucial to allow assessment of the risks of bias and transparent interpretation of the results of studies. 
Whilst this review echoes the findings of many other assessments of reporting reviews, that reporting needs to be 
improved, we provide clear guidance of items which require particular attention as they are frequently poorly 
reported. Of note, researchers should pay careful attention to the reporting of how clusters and participants are 
recruited or sampled; and whether this was done without knowledge of the randomised allocation. Exactly how the 
design, results and interpretation of a SW-CRT should be reported is different to that of individually randomised and 
parallel cluster trials. Any future updates of the CONSORT extension for SW-CRTs should pay careful attention to the 
wording and relevance of items with low agreement between reviewers, including why the trial stopped, which may 
not be relevant to many SW-CRTs. Future developments of guidelines for reporting might assess reliability before 
publication and as a final stage in the development of the reporting guideline.  
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Table1. Characteristics of the included stepped-wedge cluster randomized trial study reports 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IQR: interquartile range. 
  
Characteristic 
 
Frequency (%) 
N = 25 reports in 
total 
Publication year  
   2017 13 (52%) 
   2016 12 (48%) 
Journal Impact Factor  
   Median (IQR) 2.8 [2.1-9.8] 
Country of study   
High income country  
   UK or Ireland 5 (20%) 
   Netherlands 5 (20%) 
   Canada or US 3 (12%) 
   Australia  2 (8%) 
   Other  3 (12%) 
Low income country 5 (20%) 
Middle income country 1 (4%) 
Multiple countries of different levels 1 (4%) 
Type of setting   
   Health-care 20 (80%) 
   Non health-care 5 (20%) 
Type of clusters   
   General practice 3 (12%) 
   Hospital/Ward/Specialities 9 (36%) 
   Nursing homes 2 (8%) 
   Other cluster in health setting 3 (12%) 
   Geographical unit 5 (20%) 
   Other / Unclear 3 (12%) 
Number of sequences  
   Three 5 (20%) 
   Four 6 (24%) 
   Five 2 (8%) 
   Six or more 11 (44%) 
   Unclear 1 (4%) 
   Median (IQR) 5 (4-8) 
Number of clusters  
   Three 1(4%) 
   Four 4 (16%) 
   Five – Ten 5 (20%) 
   Eleven - Fifteen 5 (20%) 
   Greater than Fifteen  10 (40%) 
   Median (IQR) 13 [6-20] 
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Table 2: Percentage agreement for each item across reviewer pairs  
 
 
N 
(reviewers) 
Four-point scale Two-point scale 
 
 
 Agreement Gwet’s A1 statistic 
(95% CI) 
Agreement Gwet’s Al statistic 
(95% CI) 
Title and abstract Item 1a 44 82% 0.78 (0.52: 1.00) 100% 1.00 (0.84: 1.00) 
 Item 1b 44 55% 0.43 (0.13: 0.73) 86% 0.81 (0.54: 1.00) 
Background and 
objectives 
Item 2a 
44 41% 0.25 (-0.05: 0.55) 73% 0.49 (0.08: 0.91) 
 Item 2b 42 52% 0.41 (0.09: 0.73) 81% 0.68 (0.33: 1.00) 
Trial design Item 3a 44 45% 0.29 (0.00: 0.59) 59% 0.23 (-0.23: 0.68) 
 Item 3b 34 65% 0.56 (0.22: 0.91) 76% 0.55 (0.10: 1.00) 
Participants Item 4a 44 50% 0.35 (0.05: 0.65) 64% 0.39 (-0.05: 0.83) 
 Item 4b 42 43% 0.30 (-0.01: 0.60) 76% 0.64 (0.27: 1.00) 
Interventions Item 5 44 59% 0.49 (0.20: 0.77) 95% 0.94 (0.75: 1.00) 
Outcomes Item 6a 42 43% 0.29 (-0.02: 0.60) 76% 0.69 (0.36: 1.00) 
 Item 6b 32 69% 0.64 (0.29: 0.99) 75% 0.61 (0.16: 1.00) 
Sample size Item 7a 42 52% 0.37 (0.06: 0.68) 71% 0.44 (0.01: 0.86) 
 Item 7b 16 75% 0.72 (0.17: 1.00) 75% 0.69 (0.12: 1.00) 
Randomisation  Item 8a 44 68% 0.60 (0.31: 0.88) 82% 0.66 (0.30: 1.00) 
 Item 8b 42 43% 0.26 (-0.04: 0.57) 57% 0.16 (-0.31: 0.63) 
Allocation  Item 9 44 59% 0.46 (0.16: 0.76) 86% 0.73 (0.40: 1.00) 
Implementation  Item 10a 44 59% 0.51 (0.21: 0.81) 82% 0.75 (0.45: 1.00) 
 Item 10b 42 43% 0.24 (-0.07: 0.55) 67% 0.35 (-0.10: 0.80) 
 Item 10c 42 52% 0.38 (0.06: 0.69) 90% 0.82 (0.52: 1.00) 
Blinding Item 11a 30 60% 0.51 (0.12: 0.89) 80% 0.69 (0.26: 1.00) 
 Item 11b 18 56% 0.44 (-0.05: 0.93) 56% 0.21 (-0.45: 0.88) 
Statistical analysis Item 12a 44 55% 0.41 (0.11: 0.72) 77% 0.63 (0.27: 0.99) 
 Item 12b 40 50% 0.37 (0.04: 0.70) 85% 0.74 (0.39: 1.00) 
Flow diagram Item 13a 44 27% 0.05 (-0.22: 0.31) 59% 0.26 (-0.21: 0.72) 
 Item 13b 42 29% 0.06 (-0.21: 0.33) 71% 0.47 (0.05: 0.89) 
Recruitment Item 14a 44 50% 0.34 (0.04: 0.64) 86% 0.73 (0.40: 1.00) 
 Item 14b 28 36% 0.19 (-0.16: 0.55) 50% 0.02 (-0.55: 0.58) 
Baseline data Item 15 44 64% 0.54 (0.25: 0.83) 86% 0.81 (0.53: 1.00) 
Numbers analysed Item 16 42 19% -0.08 (-0.31: 0.16) 62% 0.26 (-0.21: 0.72) 
Outcomes and 
estimation  
Item 17a 
42 57% 0.45 (0.14: 0.75) 71% 0.55 (0.15: 0.95) 
 Item 17b 30 40% 0.22 (-0.14: 0.59) 67% 0.34 (-0.17: 0.86) 
Auxiliary analysis Item 18 38 47% 0.30 (-0.02: 0.63) 68% 0.38 (-0.09: 0.85) 
Harms Item 19 34 71% 0.66 (0.32: 1.00) 88% 0.82 (0.48: 1.00) 
Limitations Item 20 40 45% 0.29 (-0.02: 0.59) 75% 0.57 (0.18: 0.96) 
Generalisability  Item 21 36 56% 0.41 (0.06: 0.75) 67% 0.34 (-0.13: 0.82) 
Interpretation  Item 22 40 40% 0.25 (-0.06: 0.56) 60% 0.37 (-0.09: 0.83) 
Registration  Item 23 42 81% 0.77 (0.51: 1.00) 90% 0.82 (0.51: 1.00) 
Protocol Item 24 38 79% 0.74 (0.44: 1.00) 95% 0.91 (0.63: 1.00) 
Funding  Item 25 42 76% 0.73 (0.46: 1.00) 90% 0.88 (0.63: 1.00) 
Research ethics Item 26 42 71% 0.62 (0.31: 0.93) 76% 0.59 (0.20: 0.98) 
 All items 
(median 
 53% [43%, 
64%] 
0.41 [0.29, 0.55] 76% [67%, 
86%] 
0.62 [0.38, 0.74] 
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IQR) 
Four-point scale classifies each item as: clearly and fully reported / clearly but partially recorded / unclearly reported / not reported. Two-point 
scale classified each item as: clearly and fully reported or partially recorded / unclearly or not reported.  Any “not applicable” are excluded.  
IQR: interquartile range. CI: Confidence Interval. N: Number of reviewers. 
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Table 3: Joint assessment of the quality of reporting for 26 items of CONSORT extension for the SW-CRT 
Item Detailed description Clearly reported* 
Reported /N (%)  
Item 1a Identification as a stepped-wedge cluster randomised trial in the 
title. 15/25 (60%) 
Item 1b Structured summary of trial design, methods, results, and 
conclusions. 20/25 (80%) 
Item 2a Scientific background. Rationale for using a cluster design and 
rationale for using a stepped-wedge design 10/25 (40%) 
Item 2b Specific objectives or hypotheses 17/25 (68%) 
Item 3a Description and diagram of trial design including definition of 
cluster, number of sequences, number of clusters randomised to 
each sequence, number of periods, duration of time between 
each step, and whether the participants assessed in different 
periods are the same people, different people, or a mixture 13/24 (54%) 
Item 3b Important changes to methods after trial commencement (such 
as eligibility criteria), with reasons. 12/25 (48%) 
Item 4a Eligibility criteria for clusters and participants. 21/25 (84%) 
Item 4b Settings and locations where the data were collected. 21/23 (91%) 
Item 5 The intervention and control conditions with sufficient details to 
allow replication, including how and when they were 
administered; whether the intervention was delivered at the level 
of the cluster, the individual, or both. 21/25 (84%) 
Item 6a Completely defined pre-specified primary and secondary outcome 
measures, including how and when they were assessed. 20/25 (80%) 
Item 6b Any changes to trial outcomes after the trial commenced, with 
reasons 10/25 (40%) 
Item 7a How sample size was determined. Method of calculation and 
relevant parameters with sufficient detail so the calculation can 
be replicated. Assumptions made about correlations between 
outcomes of participants from the same cluster. 14/25 (56%) 
Item 7b When applicable, explanation of any interim analyses and 
stopping guidelines. 15/25 (60%) 
Item 8a Method used to generate the random allocation to the sequences 
of treatments. 10/24 (42%) 
Item 8b Type of randomisation; details of any constrained randomisation 
or stratification if used. 12/25 (48%) 
Item 9 Specification that allocation was based on clusters; description of 
any methods used to conceal the allocation from the clusters until 
after recruitment.  10/25 (40%) 
Item 10a Who generated the randomisation schedule, who enrolled 
clusters, and who assigned clusters to sequences 5/25 (20%) 
Item 10b Mechanism by which individual participants were included in 
clusters for the purposes of the trial (such as complete 
enumeration, random sampling; continuous 
recruitment/ascertainment, or recruitment at a fixed point in 
time), including who recruited or identified participants. 11/25 (44%) 
Item 10c Whether, from whom and when consent was sought and for 
what; whether this differed between treatment conditions. 14/25 (56%) 
Item 11a If done, who was blinded after assignment to sequences (for 
example, cluster level participants, individual level participants, 7/25 (28%) 
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those assessing outcomes) and how. 
Item 11b If relevant, description of the similarity of treatments. 16/24 (67%) 
Item 12a Statistical methods used to compare treatment conditions for 
primary and secondary outcomes including how time effects, 
clustering and repeated measures were taken into account. 17/25 (68%) 
Item 12b Methods for additional analyses, such as subgroup analyses and 
adjusted analyses. 17/25 (68%) 
Item 13a For each treatment condition or allocated sequence the numbers 
of clusters and participants who were assessed for eligibility, were 
randomly assigned, received intended treatments and were 
analysed for the primary outcome. 16/25 (64%) 
Item 13b For each treatment condition or allocated sequence, losses and 
exclusions for both clusters and participants with reasons. 14/25 (56%) 
Item 14a Dates defining the steps, initiation of intervention and deviations 
from planned dates. Dates defining recruitment and follow-up for 
participants. 14/25 (56%) 
Item 14b Why the trial ended or was stopped 17/25 (68%) 
Item 15 Baseline characteristics for the individual and cluster levels as 
applicable for each treatment condition or allocated sequence. 22/25 (88%) 
Item 16 The number of observations and clusters included in each analysis 
for each treatment condition and whether the analysis was 
according to the allocated schedule. 16/25 (64%) 
Item 17a For each primary and secondary outcome, results for each 
treatment condition, and the estimated effect size and its 
precision (such as 95% confidence interval); any correlations and 
time effects estimated in the analysis.   21/25 (84%) 
Item 17b For binary outcomes, presentation of both absolute and relative 
effect sizes is recommended. 18/25 (72%) 
Item 18 Results of any other analyses performed, including subgroup 
analyses and adjusted analyses, distinguishing pre-specified from 
exploratory. 16/24 (67%) 
Item 19 Important harms or unintended effects in each treatment 
condition (for specific guidance see CONSORT for harms). 9/25 (36%) 
Item 20 Trial limitations, addressing sources of potential bias, imprecision, 
and, if relevant, multiplicity of analyses. 16/24 (67%) 
Item 21 Generalisability (external validity, applicability) of the trial 
findings. Generalisability to clusters and/or individual participants 
(as relevant). 11/24 (46%) 
Item 22 Interpretation consistent with results, balancing benefits and 
harms, and considering other relevant evidence. 19/24 (79%) 
Item 23 Registration number and name of trial registry. 17/25 (68%) 
Item 24 Where the full trial protocol can be accessed, if available. 7/25 (28%) 
Item 25 Sources of funding and other support (such as supply of drugs), 
role of funders. 23/24 (96%) 
Item 26 Whether the study was approved by a research ethics committee, 
with identification of the review committee(s). Justification for 
any waiver or modification of informed consent requirements. 20/25 (80%) 
All  Total (out of 40) number of items clearly or fully reported (median 
[IQR]) 
28 [23 to 30] 
*Includes not applicable;  
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Table S1: Characteristics of participant reviewers performing data-abstraction in quality assessment review   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Statistician (non-academic); research statistician; medical professional 
 
  
 
N (%) 
N=50 
Highest Career Level  
    PhD student (completed or in progress) 9(18%) 
    MSc student (completed or in progress) 6(12%) 
    Post doc researcher 8(16%) 
    Lecturer 4(8%) 
    Senior lecturer/ Reader 7(14%) 
    Professor 13(26%) 
   *Other 3(6%) 
Main Occupation  
   Methodologist (Statistician) 39 (78%) 
   Trialist 2(4%) 
    Other (Clinician, other type of researcher) 9(18%) 
Type of Setting  
   Health-care 2(4%) 
   University 36(72%) 
   Health-care and University 12(24%) 
Country of Work   
   United Kingdom 42(84%) 
   France 3(6%) 
   United States 2(4%) 
   Netherlands 2(4%) 
   Australia 1(2%) 
Previous involvement in SW-CRT CONSORT statement  
   Participated in Delphi Survey 6(12%) 
   Co-author 7(14%) 
   No 37(74%) 
Previous involvement in other CONSORT statements  
   Yes 7(14%) 
   No 43(86%) 
Previous experience with SW-CRTs  
   Yes; one trial 15(30%) 
   Yes; two trials 6(12%) 
   Yes; three or more trials 8(16%) 
   No experience 21(42%) 
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Table S2: Percentage agreement for each reviewer pair across all items    
  Independent assessments  Joint assessment 
Paper ID Reviewers Agreement Gwet’s A1 
statistic  
Number items 
clearly reported^ 
(max 40) 
Study ID 2 Pair 1 56.76% 0.47 (0.25: 0.69) 11 (28%) 
Study ID 3 Pair 2    
Study ID 7 Pair 3 55.56% 0.47 (0.26: 0.68) 27 (68%) 
Study ID 8 Pair 4    
Study ID 9 Pair 5 43.24% 0.33 (0.13: 0.53) *22 (61%) 
Study ID 12 Pair 6 60.53% 0.53 (0.33: 0.73) 23 (58%) 
Study ID 18 Pair 7 51.43% 0.42 (0.21: 0.63) *26 (67%) 
Study ID 20 Pair 8    
Study ID 21 Pair 9 38.24% 0.26 (0.05: 0.47) 29 (73%) 
Study ID 22 Pair 10 41.03% 0.30 (0.10: 0.50) *19 (49%) 
Study ID 23 Pair 11 50.00% 0.41 (0.20: 0.62) 30 (75%) 
Study ID 29 Pair 12 48.65% 0.39 (0.18: 0.59) 29 (73%) 
Study ID 31 Pair 13 50.00% 0.42 (0.21: 0.62) 30 (75%) 
Study ID 32 Pair 14 39.39% 0.28 (0.07: 0.50) 23 (58%) 
Study ID 33 Pair 15 61.54% 0.55 (0.35: 0.74) 28 (70%) 
Study ID 34 Pair 16 58.33% 0.52 (0.31: 0.73) 34 (85%) 
Study ID 37 Pair 17 44.44% 0.34 (0.13: 0.55) 26 (65%) 
Study ID 39 Pair 18 54.29% 0.47 (0.25: 0.69) 12 (30%) 
Study ID 43  Pair 19 56.76% 0.49 (0.28: 0.70) 27 (68%) 
Study ID 44  Pair 20 64.52% 0.60 (0.37: 0.83) 32 (80%) 
Study ID 45  Pair 21 51.35% 0.42 (0.21: 0.62) *28 (74%) 
Study ID 46  Pair 22 82.86% 0.80 (0.62: 0.97) 26 (65%) 
Study ID 47  Pair 23 48.28% 0.41 (0.17: 0.65) 9 (23%) 
Study ID 49 Pair 24 45.16% 0.35 (0.12: 0.58) 29 (73%) 
Study ID 50  Pair 25 75.00% 0.71 (0.55: 0.88) 10 (25%) 
All Average (median [IQR])  0.42 [0.36, 0.51]  
Each pair represents two reviewers who independently reviewed the same paper and assessed quality of reporting on the two point scale for 26 items. Each pair 
reviewed a different paper. Any items rated as not applicable by reviewers are treated as a missing assessment (as this was not included on the original quality 
assessment form). Pairs with missing agreement returned only one independent assessment and not two. *At least one quality assessment for one item was 
missing in the joint assessment and denominator for percentage not 40. ^In joint assessment.  
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